Primary Myelofibrosis Clinical Trials

167 clinical trials for Primary Myelofibrosis across international registries, including 32 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia — RECRUITING · PHASE1
• A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) — RECRUITING · PHASE2
• Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes — RECRUITING · NA
• A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms — RECRUITING · PHASE1
• Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis — RECRUITING · PHASE2
• A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) — RECRUITING · PHASE3
• Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis — RECRUITING · PHASE1
• Research Platform Myelofibrosis and Anemia — RECRUITING
• Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) — RECRUITING · PHASE1
• Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm — RECRUITING
• A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) — RECRUITING · PHASE1
• Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis — RECRUITING · PHASE2
• UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy — RECRUITING · PHASE1
• A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) — RECRUITING · PHASE3
• Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms — RECRUITING · PHASE2
• Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes — RECRUITING · PHASE2
• MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) — RECRUITING
• Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib — RECRUITING · PHASE3
• Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis — RECRUITING · PHASE2
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER PHASE 3 CLINICAL STUDY TO ASSESS EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B (P1101) IN ADULT PATIENTS WITH PRE-FIBROTIC/EARLY PRIMARY MYELOFIBROSIS OR OVERT PRIMARY MYELOFIBROSIS AT LOW OR INTERMEDIATE-1 RISK ACCORDING TO DIPSS PLUS (HOPEPMF): THE CORE STUDY AND ITS EXTENSION STUDY — RECRUITING · PHASE3
• Role of Mesenchymal Stromal Cell Derived Extracellular Vesicles of Primary Myelofibrosis Patients on CD34+ Cells — RECRUITING
• 68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis. — RECRUITING
• Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera — RECRUITING
• A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis — RECRUITING
• Myeloproliferative Neoplasms (MPNs) Patient Registry — RECRUITING
• Myeloproliferative Neoplastic Diseases Observatory From Brest — RECRUITING
• Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition — RECRUITING · PHASE1
• Asian Myeloproliferative Neoplasm (MPN) Registry — RECRUITING
• Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib — RECRUITING · PHASE1
• A RANDOMIZED, CONTROLLED PHASE 3 STUDY OF PACRITINIB VERSUS PHYSICIAN'S CHOICE IN PATIENTS WITH PRIMARY MYELOFIBROSIS, POST POLYCYTHEMIA VERA MYELOFIBROSIS, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA (PLATELETS COUNTS <50,000/MCL) — RECRUITING · PHASE3
• AN OPEN-LABEL, PHASE 2A/2B STUDY OF KRT-232 IN SUBJECTS WITH PRIMARY MYELOFIBROSIS (PMF), POST¿POLYCYTHEMIA VERA MF (POST¿PV-MF), OR POST¿ESSENTIAL THROMBOCYTHEMIA MF (POST ET-MF) WHO HAVE FAILED RUXOLITINIB — RECRUITING · PHASE2
• A RANDOMIZED CONTROLLED PHASE 3 STUDY OF ORAL PACRITINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH THROMBOCYTOPENIA AND PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS. — RECRUITING · PHASE3
• P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk — ACTIVE_NOT_RECRUITING · PHASE3
• Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis — COMPLETED · PHASE1
• Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) — ACTIVE_NOT_RECRUITING · PHASE3
• An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions — ACTIVE_NOT_RECRUITING · PHASE3
• CINC424A2X01B Rollover Protocol — ACTIVE_NOT_RECRUITING · PHASE4
• Extended Access of Momelotinib in Adults With Myelofibrosis — ACTIVE_NOT_RECRUITING · PHASE2
• Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis — ACTIVE_NOT_RECRUITING · PHASE2
• Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors — TERMINATED · PHASE2
• A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies — COMPLETED · PHASE1
• Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants — ACTIVE_NOT_RECRUITING · PHASE2
• Study of Canakinumab in Patients With Myelofibrosis — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis — ACTIVE_NOT_RECRUITING · PHASE3
• Decitabine in Treating Patients With Myelofibrosis — ACTIVE_NOT_RECRUITING · PHASE2
• A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies — COMPLETED · PHASE2
• Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis — ACTIVE_NOT_RECRUITING · PHASE2
• Fedratinib in Combination With Nivolumab — COMPLETED · PHASE2
• Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm — COMPLETED · PHASE2
• JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis — COMPLETED · PHASE2

Refine this search